Needham Maintains Buy on ShockWave Medical, Lowers Price Target to $265
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a 'Buy' rating on ShockWave Medical (NASDAQ:SWAV) but lowers the price target from $330 to $265.
October 24, 2023 | 9:49 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst maintains a 'Buy' rating on ShockWave Medical but lowers the price target from $330 to $265.
The news is directly related to ShockWave Medical. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100